ArticleArchives of medical science : AMS2016
The role of cystatin-C in the confirmation of reduced glomerular filtration rate among the oldest old.
Article in Archives of medical science : AMS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Cardiovascular Risk Prediction in Older Adults.Current atherosclerosis reports · 2025Review
- CYSTATIN C-A Monitoring Perspective of Chronic Kidney Disease in Patients with Diabetes.International journal of molecular sciences · 2024Review
- Cystatin C as a biomarker of chronic kidney disease: latest developments.Expert review of molecular diagnostics · 2020Review
- Association of circulating cystatin C levels with type 2 diabetes mellitus: a systematic review and meta-analysis.Archives of medical science : AMS · 2020Review
- Calculated parenteral initial therapy of bacterial infections: Antibiotic treatment in the elderly.GMS infectious diseases · 2020Article
- Association of retinol binding protein-4, cystatin C, homocysteine and high-sensitivity C-reactive protein levels in patients with newly diagnosed type 2 diabetes mellitus.Archives of medical science : AMS · 2019Article
- Relationship of reduced glomerular filtration rate with alterations in plasma free amino acids and uric acid evaluated in healthy control and hypertensive subjects.Scientific reports · 2019Article
- A PheWAS study of a large observational epidemiological cohort of African Americans from the REGARDS study.BMC medical genomics · 2019Article
- Article
- Two elderly patients with normal creatinine and elevated cystatin C - a case report.BMC nephrology · 2017Article
- Influence of renal function on the association between homocysteine level and risk of ischemic stroke.American journal of translational research · 2017Article
- Pretreatment Serum Cystatin C Levels Predict Renal Function, but Not Tumor Characteristics, in Patients with Prostate Neoplasia.BioMed research international · 2017Article
- [Renal replacement therapy in the elderly].Zeitschrift fur Gerontologie und Geriatrie · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
introductionCurrent guidelines suggest using cystatin-C to confirm a reduced creatinine-based estimated glomerular filtration rate (eGFRcr) when the latter is thought to be inaccurate. Older adults have reduced muscle mass, which may affect the accuracy of eGFRcr. We evaluated the use of cystatin-C-based eGFR (eGFRcys) to confirm reduced eGFRcr among adults ≥ 80 years of age and, for comparison, younger adults. MATERIAL AND
methodsWe analyzed data from 3,059 REasons for Geographic And Racial Differences in Stroke (REGARDS) study participants with reduced eGFRcr (< 60 ml/min/1.73 m(2)) enrolled in 2003-2007 who were not on dialysis. eGFRcr and eGFRcys were calculated using age, sex and race-adjusted equations. Confirmed reduced eGFRcr was defined as eGFRcys < 60 ml/min/1.73 m(2). Prevalence of chronic kidney disease complications at baseline and all-cause mortality up to March 2012 were calculated. Analyses were stratified by age: < 65, 65-79 and ≥ 80 years.
resultsAmong participants < 65, 65-79 and ≥ 80 years of age, 76.5%, 85.7% and 92.5%, respectively, had reduced eGFRcr confirmed with eGFRcys (p < 0.001). Among participants ≥ 80 years of age, those with reduced eGFRcr confirmed with eGFRcys had higher prevalence of hypertension (79.1% vs. 65.1%, p = 0.03) and albuminuria (38.3% vs. 22.7%, p = 0.04) and higher risk for all-cause mortality (hazard ratio: 2.43; 95% confidence interval: 1.19-5.01) as compared with those in whom reduced eGFRcr was not confirmed by eGFRcys.
conclusionsReduced eGFRcr was confirmed using eGFRcys for the vast majority of adults ≥ 80 years. These results suggest that using cystatin-C to confirm a reduced eGFRcr may not be necessary among the oldest old.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.